At the recent North American Cystic Fibrosis Conference in Denver, George Retsch-Bogart, MD, professor of pediatrics and co-director of the UNC Cystic Fibrosis Therapeutics Development Center, received the Cystic Fibrosis Foundation’s 2018 Richard C. Talamo Distinguished Clinical Achievement Award.
At the recent North American Cystic Fibrosis Conference in Denver, George Retsch-Bogart, MD, professor of pediatrics and co-director of the UNC Cystic Fibrosis Therapeutics Development Center, received the Cystic Fibrosis Foundation’s 2018 Richard C. Talamo Distinguished Clinical Achievement Award.
This prestigious award is given to recognize individuals who have dedicated their careers to researching and caring for people with CF, and whose contributions have altered the course of this disease. Retsch-Bogart was specifically honored for his work as the lead investigator for the development of inhaled aztreonam (Cayston®) and as chair of the steering committee for the pivotal Pseudomonas aeruginosa eradication trial, EPIC.
He also was recognized for his 12 years of dedicated service as the faculty director of the CF Therapeutics Development Network (TDN), where he developed the advanced training program, EQUIP-CR, for TDN research teams. Retsch-Bogart also led efforts to coordinate clinical trials between the TDN and the European Cystic Fibrosis Clinical Trials Network and is the chairman of the Clinical Research Executive Committee.
Retsch-Bogart has accomplished all this while being loved by patients and parents for his clinical care and his leadership as co-director of the UNC Pediatric CF Program for 24 years!
Additional information about this award can be found here.